Posted by AGORACOM
at 8:33 AM on Monday, April 29th, 2019
OTTAWA, April 29, 2019 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra†or “TBPâ€), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Altus Formulation Inc. (“Altusâ€)
today announced the signing of a Joint Venture Agreement under which
the two companies will work together to develop a series of
cannabinoid-receptor targeted therapeutics addressing multiple areas of
high unmet need.
The Joint-Venture will synergize the capabilities of the two companies:
Products: The companies have identified product candidates in the
fields of pain, oncology and ophthalmology, addressing a total market
size of over $10BN. (Source: MedTrack™)
New Routes of Administration: Altus’ SmartCelle™ insoluble drug
delivery platform enables intravenous, topical, intra-nasal and oral
delivery. Smartcelle’s™ proven ability to enhance the solubility of
cannabinoids permits increased oral absorption and enables low volume
parenteral and transmucosal delivery. Intellitab™ and Flexitab™
technologies will deliver Safer to Use™ products to patients.
New Intellectual Property: Altus’ distinct drug delivery
technologies provide Tetra with significant strategic advantages over
the competition and will enable Tetra to significantly improve some of
the current products under development. In addition to SmartCelle™ these
include Intellitab™ abuse deterrent technology platform and, Flexitab™
breakable sustained release tablet technology for enhanced dosing
flexibility. All platforms are protected by patents enforced globally.
Commercial Development, Manufacturing and Supply. Combining Altus
and Tetra capabilities ensures these essential parts of the value chain
are addressed early and efficiently.
Dr. Guy Chamberland, CEO and CSO of Tetra stated, “We are extremely
excited about finalizing this agreement which will enable us to improve
existing products and will allow us to exploit a number of different
delivery mechanisms including Intra-Nasal, Intravenous and Oral
Sustained Release Tablets. Furthermore, Altus’ technology will play a
key role in strengthening Tetra’s Intellectual Property for its product
portfolio. This newly created joint-venture will also serve to benefit
our patients, their care providers and help us in our quest to replace
the use of opioids.â€
Damon Smith President and CEO of Altus Formulations Inc. added, “We
believe that by targeting cannabinoid receptors we open up a range of
therapeutic pathways unaddressed by today’s medications. Whether alone
or in combination, we believe such medications can provide great value
to patients, not least to those suffering the blight of undertreated
pain. By combining our capabilities and focusing our resources to
generate the right drug for the right patient, the Tetra/Altus joint
venture overcomes many of the hurdles that have dogged cannabinoid
medicine commercialization in the past. We greatly look forward to
working with the Tetra team and to bringing these products to the
market.
About Altus Formulation Inc. Altus Formulation is
a Quebec based drug formulation and development company using its
proprietary and patent protected drug delivery technologies to generate
novel, differentiated and cost-effective new products for its partners
and their patients. With a focus on Safer to Use™ formulations, Altus’
technologies include Intellitab™ abuse deterrent technology, Flexitab™
breakable extended release tablets and SmartCelle™ technologies for
delivery of low solubility large and small molecules.
About Tetra Bio-Pharma Inc. Tetra Bio-Pharma
(TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in
cannabinoid-based drug discovery and development with a Health Canada
approved, and FDA reviewed, clinical program aimed at bringing novel
prescription drugs and treatments to patients and their healthcare
providers. The Company has several subsidiaries engaged in the
development of an advanced and growing pipeline of Bio Pharmaceuticals,
Natural Health and Veterinary Health Products containing cannabis and
other medicinal plant-based elements. With patients at the core of what
we do, Tetra Bio-Pharma is focused on providing rigorous scientific
validation and safety data required for inclusion into the existing bio
pharma industry by regulators, physicians and insurance companies.
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 2:29 PM on Thursday, February 7th, 2019
Announced change in their Drug Development Plan (DDP) priorities.
This will allow Tetra to rapidly leverage the PANAG pipeline and expertise and align its research programs on indications with unmet medical needs or a higher return on investment (ROI).Â
Last Week’s Agreement to Acquire PANAG Establishes Exhaustive Dermatology and Ophthalmic Product Portfolios
ORLEANS, Ontario, Feb. 07, 2019 – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE: TBP) (OTB: TBPMF), a global leader in cannabinoid-derived drug development and discovery, today announced a change in their Drug Development Plan (DDP) priorities. This will allow Tetra to rapidly leverage the PANAG pipeline and expertise and align its research programs on indications with unmet medical needs or a higher return on investment (ROI). Through an expanded and focused pipeline, the Corporation intends to maintain its position as a leader in cannabis and cannabinoid drug development with a clear objective to generate value for shareholders.  In addition to its DDP in oncology and neuropathic pain programs, Tetra will pursue the development of prescription products in ophthalmic, dermatology as well as other pain segments.
Tetra Bio-Pharma Drug Development Plans address key therapeutic
sectors which address the medical needs of millions of patients and
represent substantial potential revenue. Priorities are summarized
below:
“Immediately following the PANAG closing we held an Executive Team
Meeting to prioritize our solid and robust prescription product pipeline
and ensure we maintain our lead in the cannabis prescription drug
market,†stated Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma.
“The products in this pipeline address high potential unmet medical
needs, such as uveitis, corneal neuropathic pain, interstitial cystitis,
fibromyalgia and glioblastoma. Some of these products will come from
PANAG’s pipeline and medical and scientific expertise. These innovative
products target disease indications with global unmet medical needs and
where we are confident that cannabinoid-derived products can play an
important role in alleviating pain, discomfort and associated symptoms.â€
Dr. Chamberland further stated, “The news on Tuesday is a reality in
the world of drug development. The safety and wellness of patients is
always Tetra’s number one priority. We also kept in mind the
importance and responsibility of taking a first cannabinoid drug to the
market. Our responsibility was to ensure timely and accurate disclosure
of the events subsequent to the results of the mycotoxin analyses of
the clinical trial lots which arrived on January 22nd and February 1st.
Tetra, and its Executive Team is engaged in a rapid transformational
change with the PANAG acquisition which will enable Tetra to mitigate
the risk that comes with developing a pharmaceutical drug while creating
value for shareholders. As some of our peers have demonstrated, a
single approved drug, even for a rare disease indication, can play a
significant role in our valuation.â€
Dr. Chamberland goes on to say, “It was my responsibility to rapidly
adjust our research priorities while we address the impurity issue and
risk to cancer patients. Although our DDP in Advanced Cancer Pain is
temporarily suspended, we had been assessing our PPP001 research data
and planned to accelerate DDP programs that address more diseases or
health conditions with a larger ROI. Down the road this transformation
will provide us with a more sustainable and robust product pipeline. The
Leadership Team is engaged to stay focused on these research
priorities, and rest assured that we will deliver value to our
shareholders.â€
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical
leader in cannabinoid-based drug discovery and development with a Health
Canada approved, and FDA reviewed, clinical program aimed at bringing
novel prescription drugs and treatments to patients and their healthcare
providers. The Company has several subsidiaries engaged in the
development of an advanced and growing pipeline of Bio Pharmaceuticals,
Natural Health and Veterinary Products containing cannabis and other
medicinal plant-based elements. With patients at the core of what we do,
Tetra Bio-Pharma is focused on providing rigorous scientific validation
and safety data required for inclusion into the existing bio pharma
industry by regulators, physicians and insurance companies.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this
release.
Forward-looking statements Some statements in
this release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will or
may occur in the future (including, without limitation, statements
regarding potential acquisitions and financings) are forward-looking
statements. Forward-looking statements are generally identifiable by use
of the words “may”, “will”, “should”, “continue”, “expect”,
“anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or
the negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company’s ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results or
events to differ materially from current expectations include, among
other things, without limitation, the inability of the Company to obtain
sufficient financing to execute the Company’s business plan;
competition; regulation and anticipated and unanticipated costs and
delays, the success of the Company’s research and development
strategies, including the products mentioned in this release, the
applicability of the discoveries made therein, the successful and timely
completion and uncertainties related to the regulatory process
including the applications for Orphan Drug Designation, the timing of
clinical trials, the timing and outcomes of regulatory or intellectual
property decisions and other risks disclosed in the Company’s public
disclosure record on file with the relevant securities regulatory
authorities. Although the Company has attempted to identify important
factors that could cause actual results or events to differ materially
from those described in forward-looking statements, there may be other
factors that cause results or events not to be as anticipated, estimated
or intended. Readers should not place undue reliance on forward-looking
statements. While no definitive documentation has yet been signed by
the parties and there is no certainty that such documentation will be
signed. The forward-looking statements included in this news release are
made as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or otherwise
unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc. Robert (Bob) Bechard Executive Vice President, Corporate Development and Licensing 514-817-2514 [email protected]
Media Contact energi PR Carol Levine [email protected] 514-288-8500 ext. 226
Tags: pharma, tsx, tsx-v Posted in Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TPB.ca Pursues Its Research Priorities Accelerating Other Drug Development Plans
Posted by AGORACOM-JC
at 7:18 PM on Wednesday, January 30th, 2019
The Proposed Transaction is expected to:
provide Tetra with the most robust Pharmaceutical and Natural Health Products pipeline of any Cannabinoid company;
provide Tetra with more pharmaceutical and natural health products;
allow Tetra to sell these products worldwide;
give Tetra access to Panag’s NHP portfolio which is not included in the present in-licensing agreement with Panag.
ORLEANS, ON, Jan. 30, 2019 - Tetra Bio-Pharma Inc. (“Tetra” or the “Company“), a leader in cannabinoid-based drug discovery and development (TSXV: TBP) (OTCQB: TBPMF), today announced it has entered into a definitive agreement (the “Agreement“) with the shareholders (the “Vendors“) of Panag Pharma Inc. (“Panag“) for the previously-announced acquisition by Tetra of all of the issued and outstanding shares in the capital of Panag (the “Proposed Transaction“).  Panag is a Canadian-based bio-tech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation.  Panag has developed innovative and patented formulations for the treatment of ocular diseases and other pain conditions such as general neuropathic pain. Their significant formulation expertise in the wellness market will allow Tetra to expand its commercial operations.
Dr. Guy Chamberland, CEO and CSO of
Tetra stated, “In completing this acquisition of Panag Pharma we have
not only acquired a large portfolio of cannabinoid derived
pharmaceutical and natural health products but also a team of scientists
that have a substantial amount of expertise in the field. Tetra
Bio-Pharma looks forward to incorporating Panag into its operations and
accelerating its various drug development programs including our
second-generation inhaled program.”
Following the closing of the Proposed Transaction, it is expected
that Panag will remain a separate subsidiary owned 100% by Tetra and
provide Tetra with additional discovery and early phase drug development
capacity. With this robust product pipeline, Tetra intends to continue
to implement its out-licensing program to generate additional revenues
via upfront payments, milestone payments, and royalties and actively
pursue the clinical development of lead products.
According to Dr. Orlando Hung, a
co-founder of Panag, “The Panag team is very excited to have this
well-timed opportunity with Tetra Bio-Pharma, allowing us to continue
our decades of translational cannabinoid research. Utilizing the
expertise and support from Tetra Bio-Pharma, we are confident that our
partnership and combined skills will position us to bring effective and
safe cannabinoid-based medications, as well as more innovative
cannabinoid delivery systems to market to help managing patients with
pain and inflammation.”
Pursuant to the Agreement, Tetra would acquire 100% of the issued and
outstanding shares of Panag for an aggregate consideration of $12,000,000,
on a debt-free basis and subject to customary post-closing adjustments.
The purchase price would be payable by Tetra delivering to the Vendors,
on the closing date of the Proposed Transaction, (i) $3,000,000 in cash and (ii) $9,000,000 payable in common shares of Tetra (“Common Shares“),
at a price per Common Share equal to the lesser of (i) the 10-day
volume weighted average price of the Common Shares ending as of the date
of the Agreement and (ii) the Discounted Market Price (as that term is
defined in the policies of the TSX Venture Exchange (“TSXV“)) of
the Common Shares as at the date that is three business days prior to
the closing date of the Proposed Acquisition. The Agreement also
contemplates the payment by Tetra to the Vendors of an aggregate amount
of up to $15,000,000 in cash in milestone
payments upon the achievement of operational targets associated with
marketing approvals and commercialization of both human and veterinary
drug products by the U.S. Food and Drug Administration (FDA) and the
European Medicines Agency (EMA). Tetra is committed to fund Panag’s
research in an amount no less than $1,200,000
annually for a period of ten years after the closing date of the
Proposed Acquisition. The milestone payments would be accelerated in the
event of a bankruptcy, insolvency, failure of Tetra to make its funding
commitments to Panag, change of control or sale of all of the assets of
Tetra at any time until December 31, 2028.
In addition, in the event of a change of control of Tetra within 24
months of the closing date of the Proposed Acquisition, the Vendors
would be entitled to receive from Tetra an additional $10 million.
Two of the Vendors, Bill Cheliak and Gregory Drohan,
are non-arm’s length parties to Tetra within the meaning of the rules
of the TSXV. Mr. Cheliak is the Chairman of the board of directors of
the Company (the “Board“) and Mr. Drohan is a director of the
Company. The Proposed Transaction will not result in the issuance of
securities to non-arm’s length parties as a group as payment of the
purchase price exceeding 10% of the number of outstanding shares of the
Company on a non-diluted basis.
The Board formed a special committee (the “Special Committee“) for purposes of evaluating the Proposed Transaction. The Special Committee was composed of Benoit Chotard and Carl Merton, both of whom have no interest in Panag or the Proposed Transaction. On December 24, 2018, the Special Committee received a fairness opinion (the “Fairness Opinion“)
from Paradigm Capital stating that the purchase price under the
Proposed Transaction is fair, from a financial point of view, to the
shareholders of Tetra. In light of the Fairness Opinion and of other
considerations and upon the recommendation of the Special Committee, the
Board approved the Proposed Transaction. Because of their interests in
the Proposed Transaction, Mr. Cheliak and Mr. Drohan recused themselves
from all meetings and discussions of the Board relating to the Proposed
Transaction and abstained from voting on the resolutions of the Board
approving the Proposed Transaction.
The Company expects that the Proposed Transaction will be completed in February 2019.
Completion of the Proposed Transaction remains subject to a number of
conditions, including the receipt of the approval of the TSXV and such
other closing conditions as are customary in transactions of this
nature. There can be no assurance that such conditions will be
satisfied and that the Proposed Transaction will be completed as
described or at all.
Neither the TSXV nor its Regulation Services Provider (as that term
is defined in the policies of the TSXV) accepts responsibility for the
adequacy or accuracy of this release.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Panag Pharma Inc. is a Canadian based bio-tech company focused on the
development of novel cannabinoid-based formulations for the treatment
of pain and inflammation. Panag believes that pain relief should be
safe, non-addictive and above all; effective. The Panag Pharma team of
PhD scientists and medical doctors are among the world’s
leading researchers and clinicians in pain treatment and management.
They bring a combined experience of over 100 years in research and
clinical care of people dealing with chronic pain and inflammatory
conditions. Panag’s current pipeline of pain relief products include
formulations for the topical application to the skin, the eye and other
mucous membranes. Recently approved by Health Canada and currently
undergoing clinical trials, Panag Pharma’s Topical AOTC provides a new
approach to the treatment of chronic pain and inflammation.
Forward-looking statements
Some statements in this release may contain forward-looking
information. All statements, other than of historical fact, that address
activities, events or developments that the Companybelieves,
expects or anticipates will or may occur in the future (including,
without limitation, statements regarding: the anticipated benefits of
the Proposed Transaction for Tetra; completion and expected timing of
the Proposed Transaction; whether the terms of the Proposed Transaction
will be as described in this press release; whether the Proposed
Transaction will be successful; the receipt of the approval of the TSXV in
respect of the Proposed Transaction) are forward-looking statements.
Forward-looking statements are generally identifiable by use of the
words “may”, “will”, “should”, “continue”, “expect”, “anticipate”,
“estimate”, “believe”, “intend”, “plan” or “project” or the negative of
these words or other variations on these words or comparable
terminology. Forward-looking statements are subject to a number of risks
and uncertainties, many of which are beyond the Company’s ability to
control or predict, that may cause the actual results of the Company to
differ materially from those discussed in the forward-looking
statements. Factors that could cause actual results or events to differ
materially from current expectations include, among other things,
without limitation, the inability of the Company to obtain sufficient
financing to execute the Company’s business plan; competition;
regulation and anticipated and unanticipated costs and delays, the
success of the Company’s research and development strategies, including
the completion of the Proposed Transaction, the applicability of the
discoveries made therein, the successful and timely completion and
uncertainties related to the regulatory process including the
applications for Orphan Drug Designation, the timing of clinical trials,
the timing and outcomes of regulatory or intellectual property
decisions and other risks disclosed in the Company’s public disclosure
record on file with the relevant securities regulatory authorities.
Although the Company has attempted to identify important factors that
could cause actual results or events to differ materially from those
described in forward-looking statements, there may be other factors that
cause results or events not to be as anticipated, estimated or
intended. Readers should not place undue reliance on forward-looking
statements. No definitive documentation has yet been signed by the
parties and there is no certainty that such documentation will be
signed. The forward-looking statements included in this news release are
made as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or otherwise
unless required by applicable securities legislation.
please contact Tetra Bio-Pharma Inc.: Guy Chamberland, Ph.D., Chief
Executive Officer and Chief Scientific Officer, 514-220-9225,
[email protected]; Media Contact: Energi PR, Carol Levine,
514-288-8500 ext. 226, [email protected]; Stephanie Engel,
416-425-9143 ext. 209, [email protected] CNW Group
2019
Tags: Cannabinoid, tsx Posted in Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Enters into Definitive Agreement to Acquire Panag Pharma Inc.
Posted by AGORACOM-JC
at 8:16 AM on Monday, January 28th, 2019
Filed a patent application for its PPP001 drug product.
Tetra’s research has led to a significant discovery that has enabled the company to apply for patent protection.
ORLEANS, Ontario, Jan. 28, 2019 — Tetra Bio-Pharma Inc (“Tetra†or the “Companyâ€) (TSX VENTURE: TBP) (OTCQB: TBPMF), a leader in cannabinoid-based drug discovery and development has announced that it filed a patent application for its PPP001 drug product. Tetra’s research has led to a significant discovery that has enabled the company to apply for patent protection.
Tetra’s research demonstrated that the class II medical device or
pipe used to combust the PPP001 drug pellet generates a unique
composition of medicinal ingredients. This composition is significantly
different from that created when heating the drug pellet in a vaporizer.
The data demonstrated that the drug produced by combustion is different
from that of the vapor and may partly explain the recognized efficacy
of smoked cannabis. The composition of the remaining chemicals was
expected to be different between smoke and vapor. This led the
Corporation to implement two separate drug development paths and allow
Tetra to commence developing second generation drugs for inhalation.
The patent covers methods of fabrication and composition of matter.
“This patent application, if granted, would provide Tetra with full
protection of its PPP001 prescription drug product placing PPP001 in the
same category as any other innovative prescription drug,†said Dr. Guy
Chamberland, CEO and CSO of Tetra Bio-Pharma. “This will give Tetra a
much longer period of exclusivity. We recognize the inherent value of
our intellectual property and the necessity to seek appropriate patents,
to the extent possible, to protect our shareholders’ investments in the
Company.â€
Dr. Chamberland further stated, “In addition, we are pleased to
announce that Tetra Natural Health’s exclusive distribution partner,
Kombucha Baby Brewing Company, has advised us that our Hemp Energy Drink
will be made available in a number of additional outlets in Ontario and
Quebec in the not too distant future. We are very encouraged by the
reaction of the market since its introduction in Q4 2018.â€
About Tetra Bio-Pharma: Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Forward-looking statements Some statements in
this release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Companybelieves, expects or
anticipates will or may occur in the future (including, without
limitation, statements regarding: the anticipated benefits of the
Proposed Transaction for Tetra; completion and expected timing of the
Proposed Transaction; whether the terms of the Proposed Transaction will
be as described in this press release; whether the Proposed Transaction
will be successful; the receipt of the approval of the TSXV in
respect of the Proposed Transaction) are forward-looking statements.
Forward-looking statements are generally identifiable by use of the
words “may”, “will”, “should”, “continue”, “expect”, “anticipate”,
“estimate”, “believe”, “intend”, “plan” or “project” or the negative of
these words or other variations on these words or comparable
terminology. Forward-looking statements are subject to a number of risks
and uncertainties, many of which are beyond the Company’s ability to
control or predict, that may cause the actual results of the Company to
differ materially from those discussed in the forward-looking
statements. Factors that could cause actual results or events to differ
materially from current expectations include, among other things,
without limitation, the inability of the Company to obtain sufficient
financing to execute the Company’s business plan; competition;
regulation and anticipated and unanticipated costs and delays, the
success of the Company’s research and development strategies, the
success of PPP001 and the Hemp Energy Drink, the applicability of the
discoveries made therein, the successful and timely completion and
uncertainties related to the regulatory process including the
applications for Orphan Drug Designation, the timing of clinical trials,
the timing and outcomes of regulatory or intellectual property
decisions and other risks disclosed in the Company’s public disclosure
record on file with the relevant securities regulatory authorities.
Although the Company has attempted to identify important factors that
could cause actual results or events to differ materially from those
described in forward-looking statements, there may be other factors that
cause results or events not to be as anticipated, estimated or
intended. Readers should not place undue reliance on forward-looking
statements. No definitive documentation has yet been signed by the
parties and there is no certainty that such documentation will be
signed. The forward-looking statements included in this news release are
made as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or otherwise
unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Guy Chamberland, Ph.D.,
Chief Executive Officer and Chief Scientific Officer
Tags: CSE, Hemp, stocks Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra $TBP.ca Natural Health’s Distribution Partner Expands Distribution Network for the Hemp Energy Drink
Posted by AGORACOM-JC
at 8:39 AM on Monday, January 14th, 2019
Announced that Mr. Derek Theriault has been hired as National Sales Director and Michael Olders has been hired as Director Operations and Logistics.
Derek Theriault, National Sales Director Michael Olders, Director Operations and Logistics
ORLEANS, Ontario, Jan. 14, 2019 — Tetra Natural Health, a subsidiary of Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF), is pleased to announce that Mr. Derek Theriault has been hired as National Sales Director and Michael Olders has been hired as Director Operations and Logistics.
Derek Theriault, National Sales Director – has 20
years’ experience within the pharmaceutical industry and has held
various sales and leadership roles during this time. He was pivotal to
the launch of several companies including the development of their sales
forces and penetration of the Canadian market. Derek has a proven track
record for strategically building market-share for several brand name
medications, over-the-counter (OTC) drugs and natural products. Derek is
recognized for his ability to lead sales teams as well as to help grow
the talent base within the organization while reaching and surpassing
the milestones that were set forth. He is also known for his passion for
coaching, his strong ethical standards and his ability to respond to
seize opportunities.
“I am very proud to add Derek Theriault and Michael Olders to the
Tetra Natural Health management team. Their combined solid experience
and track records with OTC drugs and natural health products will enable
us to grow our portfolio of products and our commercial results
significantly over the coming year and contribute to the consolidated
results of Tetra Bio-Pharma,†says Richard Giguere, Chief Executive
Officer of Tetra Natural Health.
About Tetra Natural Health: Tetra Natural Health
inc. is a subsidiary of Tetra Bio-Pharma inc. that focuses on
identification, development and marketing of hemp or cannabis-based
natural health products, or cannabinoids-based products authorized for
sale by Health Canada.
About Tetra Bio-Pharma: Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved and FDA reviewed clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma has subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this
release.
Forward-looking statements Some statements in
this release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will or
may occur in the future (including, without limitation, statements
regarding potential acquisitions and financings) are forward-looking
statements. Forward-looking statements are generally identifiable by use
of the words “may”, “will”, “should”, “continue”, “expect”,
“anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or
the negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company’s ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results or
events to differ materially from current expectations include, among
other things, without limitation, the inability of the Company to obtain
sufficient financing to execute the Company’s business plan;
competition; regulation and anticipated and unanticipated costs and
delays, the success of the Company’s research and development
strategies, the applicability of the discoveries made therein, the
successful and timely completion and uncertainties related to the
regulatory process, the timing of clinical trials, the timing and
outcomes of regulatory or intellectual property decisions and other
risks disclosed in the Company’s public disclosure record on file with
the relevant securities regulatory authorities. Although the Company has
attempted to identify important factors that could cause actual results
or events to differ materially from those described in forward-looking
statements, there may be other factors that cause results or events not
to be as anticipated, estimated or intended. Readers should not place
undue reliance on forward-looking statements. While no definitive
documentation has yet been signed by the parties and there is no
certainty that such documentation will be signed The forward-looking
statements included in this news release are made as of the date of this
news release and the Company does not undertake an obligation to
publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by
applicable securities legislation.
Posted by AGORACOM-JC
at 8:24 AM on Thursday, January 10th, 2019
Lung Association – Ontario and Tetra Bio-Pharma are excited to be partnering to fill that gap by funding a research program that will investigate various health impacts of cannabis use
The goal of this program will be to better support patients and healthcare providers with evidence-based information.
TORONTO, Jan. 10, 2019 /- With the recent legalization of recreational cannabis in Canada, a major gap has been revealed, and that is a lack of scientific research on the health effects of its use – both on the recreational and medical side.
The Lung Association – Ontario and Tetra Bio-Pharma are
excited to be partnering to fill that gap by funding a research program
that will investigate various health impacts of cannabis use. The goal
of this program will be to better support patients and healthcare
providers with evidence-based information.
“It has become very clear that more research is needed to fully
understand both the effects of smoking cannabis on your lungs, and the
utility of medical cannabis as a viable option for chronic disease pain
management and treatment,” says George Habib, President and CEO of The Lung Association – Ontario. “The Lung Association is thrilled to be taking the lead in filling these gaps in knowledge.”
The results of these important research projects will ensure there is
a larger evidence-base to pull from when educating the public and
healthcare providers about the impact of cannabis use on lung health. It
will offer healthcare providers more resources to better inform the
decisions they make on behalf of their patients around the use of
cannabis.
“Tetra Bio-Pharma is excited to join forces with The Lung Association – Ontario
to expand knowledge on the impact of smoking a cannabinoid-derived
product through several pioneering research projects,” said Dr. Guy Chamberland,
CEO and CSO of Tetra Bio-Pharma. “Access to cannabinoid-derived medical
therapies is severely limited because of an absence of rigorous safety
and efficacy data. We are committed to supporting research excellence to
enable innovation but also to establish the evidence that regulators,
physicians and insurance companies are waiting for.”
The research funded as a result of this collaboration will be driven by The Lung Association – Ontario.
It will be fully peer reviewed and administered in a completely
arms-length manner from the Funder. Funding recipients will be announced
on March 28, 2019.
About The Lung Association – Ontario The Lung Association – Ontario
is a not-for-profit organization dedicated to helping all Ontarians
breathe. Our community of donors, patients, researchers, volunteers and
professional staff work to ensure Ontarians have healthy lungs, bodies
and clean air necessary to breathe. We achieve this by promoting healthy
breathing, supporting those living with lung disease and finding future
solutions. All of this is done with the goal of delivering a future of
better breathing for all.
About Tetra Bio-Pharma Inc. Tetra
Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in
cannabinoid-based drug discovery and development with a Health Canada
approved, and FDA reviewed, clinical program aimed at bringing novel
prescription drugs and treatments to patients and their healthcare
providers. The Company has several subsidiaries engaged in the
development of an advanced and growing pipeline of Bio Pharmaceuticals,
Natural Health and Veterinary Products containing cannabinoid-derived
molecules and other medicinal plant-based elements. With patients at the
core of what we do, Tetra Bio-Pharma is focused on providing rigorous
scientific validation and safety data required for inclusion into the
existing bio pharma industry by regulators, physicians and insurance
companies. For more information visit: www.tetrabiopharma.com.
Posted by AGORACOM-JC
at 4:17 PM on Thursday, December 20th, 2018
Planning for Phase 2 Clinical Trial Underway
Announced that its Phase 1 clinical trial in healthy volunteers using vaporized PPP001 has been successfully concluded.
This trial was aimed at determining the pharmacokinetics (PK) and safety of a 4-day titration followed by a single dose of vaporized PPP001 in 12 healthy volunteers.
OTTAWA, Dec. 20, 2018 — Tetra Bio-PharmaInc.(“Tetra†or “TBPâ€) today announced that its Phase 1 clinical trial in healthy volunteers using vaporized PPP001 has been successfully concluded. This trial was aimed at determining the pharmacokinetics (PK) and safety of a 4-day titration followed by a single dose of vaporized PPP001 in 12 healthy volunteers.   Preliminary review of the human clinical data indicates that the treatment was well tolerated. Based on these positive results, Tetra Bio-Pharma expects to move into Phase 2 clinical trials in fibromyalgia patients.Â
Tetra Bio-Pharma also completed a first series of analyses of the
cannabis vapor generated by the Mighty Medic vaporizer manufactured by
Storz & Bickel, thus providing a deeper understanding of the process
of administering cannabinoids to patients. This gives health regulators
like Health Canada, a detailed view of the efficiency of the delivery
system.
“We are thrilled with the results of this trial which was completed
both on time and on budget,†stated Dr. Guy Chamberland, CEO and CSO of
Tetra Bio-Pharma. “We look forward to investigating this vaped version
of PPP001 in patients who suffer from the debilitating pain of
fibromyalgia. The Mighty Medic technology provides an alternative
delivery method for PPP001, along with a new therapeutic indication for
fibromyalgia which will give us access to a much larger patient
population. According to the National Fibromyalgia Association there are
more than 10 million people who suffer from this disease in the U.S.
alone.â€
About Tetra Bio-Pharma Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Forward-looking Statements Some statements in
this release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will or
may occur in the future (including, without limitation, statements
regarding potential acquisitions and financings) are forward-looking
statements. Forward-looking statements are generally identifiable by use
of the words “may”, “will”, “should”, “continue”, “expect”,
“anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or
the negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company’s ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results or
events to differ materially from current expectations include, among
other things, without limitation, the inability of the Company to obtain
sufficient financing to execute the Company’s business plan;
competition; regulation and anticipated and unanticipated costs and
delays, the success of the Company’s research and development
strategies, including this trial, the ability to obtain orphan drug
status, the applicability of the discoveries made therein, the
successful and timely completion and uncertainties related to the
regulatory process, the timing of clinical trials, the timing and
outcomes of regulatory or intellectual property decisions and other
risks disclosed in the Company’s public disclosure record on file with
the relevant securities regulatory authorities. Although the Company has
attempted to identify important factors that could cause actual results
or events to differ materially from those described in forward-looking
statements, there may be other factors that cause results or events not
to be as anticipated, estimated or intended. Readers should not place
undue reliance on forward-looking statements. While no definitive
documentation has yet been signed by the parties and there is no
certainty that such documentation will be signed. The forward-looking
statements included in this news release are made as of the date of this
news release and the Company does not undertake an obligation to
publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by
applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
Posted by AGORACOM-JC
at 8:25 AM on Tuesday, December 11th, 2018
Confirms its non-exclusive supply agreement for GMP-Grade THC with U.S.-based Rhodes Technologies Inc.
The supply will be used for several drug development activities including Tetra’s cannabinoid-derived products PPP002, PPP003, and PPP004, as well as for discovery phase projects.
Quality and volume of Active Pharmaceutical Ingredients (API) ensured
ORLEANS, Ontario, Dec. 11, 2018 — Tetra Bio-Pharma Inc. (“Tetra†or “TBPâ€), (TSX VENTURE: TBP) (OTCQB: TBPMF) a leader in cannabinoid-based drug discovery and development confirms its non-exclusive supply agreement for GMP-Grade THC with U.S.-based Rhodes Technologies Inc. The supply will be used for several drug development activities including Tetra’s cannabinoid-derived products PPP002, PPP003, and PPP004, as well as for discovery phase projects.  This is additional to having a supply agreement with True North Cannabis Inc.  for CBD from hemp which was necessary to meeting the demand associated with the Genacol Corporation transaction.
“With a robust development pipeline, it is essential
for Tetra to have a reliable, API supply to support our expanding needs
and avoid product shortages,†said Dr. Guy Chamberland, CEO and CSO of
Tetra Bio-Pharma. “Our agreement with Rhodes is predicated on their long
history and expertise in the production and sale of active chemical
ingredients, particularly in the area of pain management. In terms of
CBD, our suppliers are selected based on their ability to provide us
with both quality (GMP Pharmaceutical Grade) and volume. Tetra is
always mindful of the need to have consistent supply as well as back-ups
for each of the products under development.â€
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements Some statements in
this release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will or
may occur in the future (including, without limitation, statements
regarding potential acquisitions and financings) are forward-looking
statements. Forward-looking statements are generally identifiable by use
of the words “may”, “will”, “should”, “continue”, “expect”,
“anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or
the negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company’s ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results or
events to differ materially from current expectations include, among
other things, without limitation, the inability of the Company to obtain
sufficient financing to execute the Company’s business plan;
competition; regulation and anticipated and unanticipated costs and
delays, the success of the Company’s research and development
strategies, including the ability to obtain orphan drug status, the
applicability of the discoveries made therein, the successful and timely
completion and uncertainties related to the regulatory process, the
timing of clinical trials, the timing and outcomes of regulatory or
intellectual property decisions and other risks disclosed in the
Company’s public disclosure record on file with the relevant securities
regulatory authorities. Although the Company has attempted to identify
important factors that could cause actual results or events to differ
materially from those described in forward-looking statements, there may
be other factors that cause results or events not to be as anticipated,
estimated or intended. Readers should not place undue reliance on
forward-looking statements. The forward-looking statements included in
this news release are made as of the date of this news release and the
Company does not undertake an obligation to publicly update such
forward-looking statements to reflect new information, subsequent events
or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
Posted by AGORACOM-JC
at 12:45 PM on Tuesday, December 4th, 2018
Recent news regarding Aphria Inc. does not in any way affect Tetra’s business, operations, clinical and drug registration and source of supply.
Company is well funded to continue these activities in 2019 with plans to expand our clinical activities in the U.S.
“Tetra is Not a Cannabis Company†Says CEO Chamberland
ORLEANS, Ontario, Dec. 04, 2018 — Tetra Bio-Pharma Inc (“Tetra†or “TBPâ€), (TSX VENTURE: TBP) (OTCQB: TBPMF) – Recent news regarding Aphria Inc. does not in any way affect Tetra’s business, operations, clinical and drug registration and source of supply. We are well funded to continue these activities in 2019 with plans to expand our clinical activities in the U.S. We remind shareholders that we are not a cannabis company but a bio-pharmaceutical firm.
“It’s important for our shareholders to understand that Tetra is not a cannabis company. We do not grow, or sell cannabis,†said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “Like the internationally recognized GW Pharma, we are a pharmaceutical company that discovers and develops prescription drugs. This strategy is entirely different from the hundreds of licensed producers and it is what makes Tetra completely unique. Our business model has, and will continue to be, to take a pharmaceutical pathway so that cannabinoid-derived drugs are integrated into the regulated healthcare system.â€
Tetra Bio-Pharma has made tremendous progress in developing its lead products as prescription drugs and is in a strong financial position to execute on our innovative and robust business strategy. The following are some of the major achievements that have taken place this year and that reflect Tetra’s work as a bio-pharmaceutical innovator:
Obtained the Drug Establishment License for the manufacturing of PPP001;
Completed the Type B and C meetings with the U.S. FDA;
Made a bid to acquire Panag Pharma Inc. and grow its intellectual property;
Advanced the timing of its filing for PPP001 in Europe;
Signed two distribution and sales agreements with pharmaceutical companies based in Israel and Portugal for our PPP001 drug product;
Successfully setup a growing Hemp Energy Drink business and shortly after ordered 1.7 million cans for sales;
Hired senior pharmaceutical industry talent with depth of experience to oversee operations in a timely, systematic way; and
Implemented plans to ensure supply of cannabis raw materials thus avoiding back orders on drug or commercial products.
Dr. Chamberland further stated, “Tetra has never been in a stronger position in its history and looks forward to continued execution of its strategy.â€
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514 [email protected]
Posted by AGORACOM-JC
at 8:28 AM on Monday, December 3rd, 2018
Announces the delivery of twenty containers, more than 1.7 million cans of its product Hemp Energy Drink,
the first hemp energy drink in Canada, to meet growing demand in Canada and to make Hemp Energy Drink available across all regions of the country.
ORLEANS, Ontario, Dec. 03, 2018 — Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), announces the delivery of twenty containers, more than 1.7 million cans of its product Hemp Energy Drink, the first hemp energy drink in Canada, to meet growing demand in Canada and to make Hemp Energy Drink available across all regions of the country.
Hemp Energy Drink available in 3 flavours: Classic, Mango and Raspberry
Canadian consumers appreciate the qualities of Hemp Energy Drink (www.hempenergydrink.ca) that contains fewer calories and more natural ingredients than other energy drinks, and the product will be available soon everywhere in Canada in three flavors: classic, mango and raspberry.
“We are very pleased with the consumer interest for the Hemp Energy Drink since its launch. Through the agreements we have with our distribution partners, their drive and the strategy we are implementing, Canadians will soon be able to appreciate the three flavors of our cool, fresh, light, natural and 100% legal beverage,” said Richard Giguère, CEO of Tetra Natural Health.
“This 20-container delivery combined with the deployment of our distribution strategy represents an important step in our market development plan for this product over the next year. Thanks to the characteristics of our energy drink and its nutritional elements, we are confident that the Hemp Energy Drink will generate a continued enthusiasm among consumers across Canada,” added Richard Giguère.
Guy Chamberland, President and CEO of Tetra Bio-Pharma stated, “With its Hemp Energy Drink business, Tetra Natural Health will allow the corporation to achieve significant orders and sales over the coming year. These orders demonstrate that the new team has established a viable natural health and wellness product business that will translate into significant revenues for the coming fiscal year, starting in Q1 2019.”
About Tetra Natural Health
Tetra Natural Health inc. is a subsidiary of Tetra Bio-Pharma inc. that focuses on identification, development and marketing of hemp or cannabis-based natural health products, or cannabinoids-based products authorized for sale by Health Canada.
About Tetra Bio-Pharma Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of various product launches including the one discussed in this release, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For more information, please contact:
Richard Giguère
CEO
Tetra Natural Health
T 348-899-7575 ext.210 [email protected]
Media Contact
Daniel Granger
ACJ Communication
T. 514Â 840-7990
M. 514Â 232 1556 [email protected]
Charlotte Blanche
T. 514 840-1235 poste 7772
M. 514 914-0593 [email protected]
